Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

 Fundus Disease Group of Ophthalmological Society of Chinese Medical Association ,  Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association , Expert Group of Expert Consensus for Pars Plana Vitrectomy Treatment of Type 2 Diabetic Retinopathy

Corresponding author：

Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Email: dr_lixiaoxin@163.com; Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association, Email: drxuxun@sjtu.edu.cn

Keywords：

Proliferative diabetic retinopathy; Pars plana vitrectomy; Evidence-based medicine; Criterion; Expert consensus

DOI：

10.3760/cma.j.cn511434-20240729-00286

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Proliferative diabetic retinopathy (PDR) is more advanced stage in diabetic retinopathy (DR), often with vitreous hemorrhages and traction retinal detachment which seriously affects patients' vision and even leads to severe visual impairment. Pars plana vitrectomy is an effective treatment for PDR. However, the operation procedure is quite complexed. Inadequate management can negatively impact postoperative vision or even lead to complications. Therefore, it is very important to clarify the surgical indications and standardize the operating procedures of PDR. To this end, Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy focus on 9 key clinical issues, based on the latest evidence-based medical evidence, combined with international guidelines and China's social and economic development. Recommendations were made on the selection of DR Surgery timing, perioperative blood glucose management, surgical mode selection, formulation of surgical operation plan, drug combination or laser therapy, etc., which formed China's expert consensus on pars plana vitrectomy in the treatment of type 2 DR. This consensus is applicable to Chinese doctors specializing in fundus diseases and doctors engaged in fundus diseases, aiming to provide scientific guidance for vitreous surgery treatment of PDR patients, assist clinical decision-making, and further improve the level of surgical treatment of DR in China.

Citation： Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert Consensus for Pars Plana Vitrectomy Treatment of Type 2 Diabetic Retinopathy. Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2024, 40(9): 663-686. doi: 10.3760/cma.j.cn511434-20240729-00286 Copy

1.	Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2011, 52(2): 1156-1163. DOI: 10.1167/iovs.10-6293.
2.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
3.	中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association. Clinical diagnosis and treatment guidelines for diabetic retinopathy in China (2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
4.	中华医学会眼科学分会眼底病学组. 我国主要眼底病慢病管理专家共识[J]. 中华眼底病杂志, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association. National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach[J]. Chin J Ocul Fundus Dis, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.
5.	高宁, 邸瑢, 谢安明, 等. PDR合并玻璃体积血的玻璃体手术时机对术后远期疗效的影响[J]. 国际眼科杂志, 2017, 17(9): 1738-1740. DOI: 10.3980/j.issn.1672-5123.2017.9.34.Gao N, Di R, Xie AM, et al. Effect of vitrectomy timing on long-term efficacy in patients with vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Int Eye Sci, 2017, 17(9): 1738-1740. DOI: 10.3980/j.issn.1672-5123.2017.9.34.
6.	Fassbender JM, Ozkok A, Canter H, et al. A comparison of immediate and delayed vitrectomy for the management of vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(1): 35-41. DOI: 10.3928/23258160-20151214-05.
7.	Cheisson G, Jacqueminet S, Cosson E, et al. Perioperative management of adult diabetic patients. Preoperative period[J]. Anaesth Crit Care Pain Med, 2018, 37(Suppl 1): S9-19. DOI: 10.1016/j.accpm.2018.02.020.
8.	Jinjing W, Kang C, Xufei L, et al. Chinese clinical practice guidelines for perioperative blood glucose management[J/OL]. Diabetes Metab Res Rev, 2021, 37(7): e3439[2021-02-19]. https://pubmed.ncbi.nlm.nih.gov/33605539/. DOI: 10.1002/dmrr.3439.
9.	中华医学会麻醉学分会. 围术期血糖管理专家共识(快捷版)[J]. 临床麻醉学杂志, 2016, 32(1): 93-95.Chinese Society of Anesthesiology. Expert consensus on perioperative blood glucose management (expression edition)[J]. J Clin Anesthesiol, 2016, 32(1): 93-95.
10.	Qu J, Chen X, Liu Q, et al. Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: a randomized controlled trial[J/OL]. Front Public Health, 2022, 10: 1067670[2023-01-11]. https://pubmed.ncbi.nlm.nih.gov/36711366/. DOI: 10.3389/fpubh.2022.1067670.
11.	Li S, Yang Y, Zou J, et al. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage[J]. BMC Ophthalmol, 2022, 22(1): 63. DOI: 10.1111/epi.17350.
12.	Li B, Li MD, Ye JJ, et al. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy[J]. Chin Med J (Engl), 2020, 133(6): 664-669. DOI: 10.1177/0956462420932688.
13.	Arevalo JF, Lasave AF, Kozak I, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial[J]. Am J Ophthalmol, 2019, 207: 279-287. DOI: 10.1016/j.ajo.2019.05.007.
14.	Faisal SM, Tahir MA, Cheema AM, et al. Pars plana vitrectomy in vitreous hemorrhage with or without intravitreal bevacizumab a comparative overview[J]. Pak J Med Sci, 2018, 34(1): 221-225. DOI: 10.12669/pjms.341.12683.
15.	Comyn O, Wickham L, Charteris DG, et al. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)[J]. Eye (Lond), 2017, 31(9): 1253-1258. DOI: 10.1038/eye.2017.75.
16.	Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy[J/OL]. J Ophthalmol, 2016, 2016: 2473234[2016-03-13]. https://pubmed.ncbi.nlm.nih.gov/27034822/. DOI: 10.1155/2016/2473234.
17.	Su L, Ren X, Wei H, et al. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy[J]. Retina, 2016, 36(5): 938-943. DOI: 10.1097/iae.0000000000000900.
18.	Manabe A, Shimada H, Hattori T, et al. Randomized controlled study of intravitreal bevacizumab 0.16 mg injected one day before surgery for proliferative diabetic retinopathy[J]. Retina, 2015, 35(9): 1800-1807. DOI: 10.1097/IAE.0000000000000577.
19.	Zaman Y, Rehman AU, Memon AF. Intravitreal avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy[J]. Pak J Med Sci, 2013, 29(2): 590-592. DOI: 10.12669/pjms.292.3044.
20.	Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1[J]. Arch Ophthalmol, 2012, 130(9): 1127-1134. DOI: 10.1001/archophthalmol.2012.1611.
21.	Farahvash MS, Majidi AR, Roohipoor R, et al. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage[J]. Retina, 2011, 31(7): 1254-1260. DOI: 10.1097/IAE.0b013e31820a68e5.
22.	di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2010, 248(6): 785-791. DOI: 10.1007/s00417-010-1303-3.
23.	Hernández-Da Mota SE, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2010, 20(6): 1047-1052. DOI: 10.1177/11206721 1002000604.
24.	Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
25.	Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(6): 837-842. DOI: 10.1007/s00417-008-0774-y.
26.	Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial[J]. Ophthalmology, 2009, 116(10): 1943-1948. DOI: 10.1016/j.ophtha.2009.07.001.
27.	El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy[J]. Clin Ophthalmol, 2008, 2(4): 709-716.
28.	Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy[J]. Ophthalmology, 2011, 118(11): 2218-2226. DOI: 10.1016/j.ophtha.2011.03.036.
29.	Yang Z, Di Y, Ye J, et al. Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1171628[2023-05-26]. https://pubmed.ncbi.nlm.nih.gov/37305048/. DOI: 10.3389/fendo.2023.1171628.
30.	Ding Y, Su N, Luan J, et al. Effect of intravitreal conbercept injection on complications of pars plana vitrectomy in patients with proliferative diabetic retinopathy[J]. J Pers Med, 2023, 13(4): 572. DOI: 10.3390/jpm13040572.
31.	Wang DY, Zhao XY, Zhang WF, et al. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis[J/OL]. Sci Rep, 2020, 10(1): 18880[2020-11-03]. https://pubmed.ncbi.nlm.nih.gov/33144606/. DOI: 10.1038/s41598-020-75896-8.
32.	Li H, Niu Y, Rong A, et al. Effect of adjunctive intravitreal conbercept injection at the end of 25G vitrectomy on severe proliferative diabetic retinopathy: 6-month outcomes of a randomised controlled trial[J]. Ophthalmol Ther, 2023, 12(2): 1173-1180. DOI: 10.1007/s40123-023-00664-6.
33.	Jiang T, Gu J, Zhang P, et al. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study[J]. BMC Ophthalmol, 2020, 20(1): 43. DOI: 10.1186/s12886-020-1321-9.
34.	Ren X, Bu S, Zhang X, et al. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy[J]. Eye (Lond), 2019, 33(7): 1177-1183. DOI: 10.1038/s41433-019-0396-0.
35.	Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA, 2015, 314(20): 2137-2146. DOI: 10.1001/jama.2015.15217.
36.	Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
37.	Suzuki Y, Adachi K, Maeda N, et al. Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation[J]. Int J Retina Vitreous, 2020, 6: 24. DOI: 10.1186/s40942-020-00222-3.
38.	Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy - the PRIDE study[J/OL]. Acta Ophthalmol, 2020, 98(5): e530-e539[2019-12-06]. https://pubmed.ncbi.nlm.nih.gov/31808278/. DOI: 10.1111/aos.14312.
39.	Williams DF, Williams GA, Hartz A, et al. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique[J]. Ophthalmology, 1989, 96(6): 752-758. DOI: 10.1016/s0161-6420(89)32813-2.
40.	Han DP, Murphy ML, Mieler WF. A modified en bloc excision technique during vitrectomy for diabetic traction retinal detachment. Results and complications[J]. Ophthalmology, 1994, 101(5): 803-808. DOI: 10.1016/s0161-6420(94)31255-3.
41.	黎晓新, 姜燕荣, 尹红, 等. 膜分割和膜清除方法对增生性糖尿病视网膜病变患者玻璃体手术效果的影响[J]. 中华眼科杂志, 2004, 40(7): 439-442. DOI: 10.3760/j:issn:0412-4081.2004.07.003.Li XX, Jiang YR, Yin H, et al. Influence of membrane dissection and en bloc excision on the outcome of vitreous surgery in proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2004, 40(7): 439-442. DOI: 10.3760/j:issn:0412-4081.2004.07.003.
42.	姚昱欧, 梁建宏, 黎晓新. 微切口玻璃体视网膜手术治疗增生型糖尿病视网膜病变合并牵拉性视网膜脱离的疗效观察[J]. 中华眼底病杂志, 2016, 32(5): 495-499. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.009.Yao YO, Liang JH, Li XX. Clinical effect of small-gauge vitrectomy for proliferative diabetic retinopathy with tractional retinal detachment[J]. Chin J Ocul Fundus Dis, 2016, 32(5): 495-499. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.009.
43.	梁建宏, 黎晓新. 增生型糖尿病视网膜病变玻璃体切割手术中眼内填充物和抗血管内皮生长因子药物应用利弊[J]. 中华眼底病杂志, 2016, 32(5): 527-528. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.016.Liang JH, Li XX. Advantages and disadvantages of intraocular fillers and anti-vascular endothelial growth factor drugs used in vitrectomy for proliferative diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2016, 32(5): 527-528. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.016.
44.	Meier P, Wiedemann P. Vitrectomy for traction macular detachment in diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 1997, 235(9): 569-574. DOI: 10.1007/BF00947086.
45.	Kakehashi A. Total en bloc excision: a modified vitrectomy technique for proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2002, 134(5): 763-765. DOI: 10.1016/s0002-9394(02)01680-x.
46.	郑传珍, 任新军, 柯屹峰, 等. 最小量化玻璃体切除术治疗严重增生性糖尿病视网膜病变的初步观察[J]. 中华眼科杂志, 2021, 57(6): 440-446. DOI: 10.3760/cma.j.cn112142-20200812-00538.Zheng CZ, Ren XJ, Ke YF, et al. Minimally invasive vitrectomy for the treatment of severe proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2021, 57(6): 440-446. DOI: 10.3760/cma.j.cn112142-20200812-00538.
47.	Vaziri K, Schwartz SG, Kishor KS, et al. Tamponade in the surgical management of retinal detachment[J]. Clin Ophthalmol, 2016, 10: 471-476. DOI: 10.2147/OPTH.S98529.
48.	Kreissig I. The perfluorocarbon gases[M]//Kreissig I. Practical guide to minimal surgery for retinal detachment. 1st ed. Stuttgart: Thieme, 2000: 129-132.Kreissig I. The perfluorocarbon gases[M]//Kreissig I. Practical guide to minimal surgery for retinal detachment. 1st ed. Stuttgart: Thieme, 2000: 129-132.
49.	Williamson TH. Principles of internal tamponade[M]//Williamson TH. Vitreoretinal surgery. 3rd ed. Berlin: Springer, 2021: 93-133.Williamson TH. Principles of internal tamponade[M]//Williamson TH. Vitreoretinal surgery. 3rd ed. Berlin: Springer, 2021: 93-133.
50.	Balakrishnan D, Jain B, Nayaka A, et al. Role of tamponade in vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage[J]. Semin Ophthalmol, 2017, 32(4): 488-491. DOI: 10.3109/08820538.2015.1120757.
51.	陶勇, 姜燕荣, 黎晓新. 增生性糖尿病视网膜病变患者玻璃体手术不同眼内填充物的效果分析[J]. 眼科新进展, 2008, 28(2): 119-121. DOI: 10.3969/j.issn.1003-5141.2008.02.012.Tao Y, Jiang YR, Li XX. Different intraocular tamponade during vitrectomy on proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2008, 28(2): 119-121. DOI: 10.3969/j.issn.1003-5141.2008.02.012.
52.	Rush RB, Velazquez JC, Rosales CR, et al. Gas tamponade for the prevention of postoperative vitreous hemorrhaging after diabetic vitrectomy: a randomized clinical trial[J]. Am J Ophthalmol, 2022, 242: 173-180. DOI: 10.1016/j.ajo.2022.06.015.
53.	Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2017, 237(4): 185-222. DOI: 10.1159/000458539.
54.	Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group[J]. Eye (Lond), 2020, 34(Suppl 1): S1-51. DOI: 10.1038/s41433-020-0961-6.
55.	Raizada S, Al Kandari J, Al Diab F, et al. Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional diabetic macular edema. A prospective, randomized comparative study[J]. Indian J Ophthalmol, 2015, 63(6): 504-510. DOI: 10.4103/0301-4738.162602.
56.	Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema[J]. Retina, 2008, 28(3): 420-426. DOI: 10.1097/IAE.0b013e318159e7d2.
57.	Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial[J]. Graefe's Arch Clin Exp Ophthalmol, 2011, 249(7): 997-1008. DOI: 10.1007/s00417-010-1610-8.
58.	Kumagai K, Furukawa M, Ogino N, et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema[J]. Retina, 2009, 29(4): 464-472. DOI: 10.1097/IAE.0b013e31819c632f.
59.	Kumagai K, Hangai M, Ogino N, et al. Effect of interal limiting membrane peeling on long-term visual outcomes for diabetic macular edema[J]. Retina, 2015, 35(7): 1422-1428. DOI: 10.1097/IAE.0000000000000497.
60.	Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema[J]. Retina, 2006, 26(1): 5-13. DOI: 10.1097/00006982-200601000-00002.
61.	Yamakoshi T, Kachi S, Sugita J, et al. Triamcinolone-assisted removal of internal limiting membrane enhances the effect of vitrectomy for diabetic macular edema[J]. Ophthalmic Res, 2009, 41(4): 203-209. DOI: 10.1159/000217724.
62.	Yamamoto T, Hitani K, Sato Y, et al. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal[J]. Ophthalmologica, 2005, 219(4): 206-213. DOI: 10.1159/000085729.
63.	Browning DJ, Lee C, Stewart MW, et al. Vitrectomy for center-involved diabetic macular edema[J]. Clin Ophthalmol, 2016, 10: 735-742. DOI: 10.2147/OPTH.S104906.
64.	Lee JY, Jeong HS, Lee DY, et al. Early postoperative intraocular pressure stability after combined 23-gauge sutureless vitrectomy and cataract surgery in patients with proliferative diabetic retinopathy[J]. Retina, 2012, 32(9): 1767-1774. DOI: 10.1097/IAE.0b013e3182475ad6.
65.	Park SP, Ahn JK, Lee GH. Morphologic changes in the anterior segment after phacovitrectomy for proliferative diabetic retinopathy[J]. J Cataract Refract Surg, 2009, 35(5): 868-873. DOI: 10.1016/j.jcrs.2008.12.032.
66.	Kadonosono K, Matsumoto S, Uchio E, et al. Iris neovascularization after vitrectomy combined with phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy[J]. Ophthalmic Surg Lasers, 2001, 32(1): 19-24. DOI: 10.3928/1542-8877-20010101-05.
67.	Tseng HY, Wu WC, Hsu SY. Comparison of vitrectomy alone and combined vitrectomy, phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy[J]. Kaohsiung J Med Sci, 2007, 23(7): 339-343. DOI: 10.1016/S1607-551X(09)70419-X.
68.	刘大川, 吴航, 郭丽. 玻璃体切除联合白内障手术治疗增生性糖尿病视网膜病变的临床效果[J]. 中华眼科杂志, 2007, 43(4): 346-349. DOI: 10.3760/j.issn:0412-4081.2007.04.012.Liu DC, Wu H, Guo L. Vitrectomy combined with phacoemulsification and intraocular lens implantation for treatment of proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2007, 43(4): 346-349. DOI: 10.3760/j.issn:0412-4081.2007.04.012.
69.	王萍, 陈松, 何广辉, 等. 不同联合手术方式治疗增生性糖尿病视网膜病变的有效性及并发症[J]. 国际眼科杂志, 2017, 17(5): 970-973. DOI: 10.3980/j.issn.1672-5123.2017.5.44.Wang P, Chen S, He GH, et al. Effect and complications of different combined surgeries for proliferative diabetic retinopathy[J]. Int Eye Sci, 2017, 17(5): 970-973. DOI: 10.3980/j.issn.1672-5123.2017.5.44.

1. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2011, 52(2): 1156-1163. DOI: 10.1167/iovs.10-6293.
2. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
3. 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association. Clinical diagnosis and treatment guidelines for diabetic retinopathy in China (2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
4. 中华医学会眼科学分会眼底病学组. 我国主要眼底病慢病管理专家共识[J]. 中华眼底病杂志, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association. National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach[J]. Chin J Ocul Fundus Dis, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.
5. 高宁, 邸瑢, 谢安明, 等. PDR合并玻璃体积血的玻璃体手术时机对术后远期疗效的影响[J]. 国际眼科杂志, 2017, 17(9): 1738-1740. DOI: 10.3980/j.issn.1672-5123.2017.9.34.Gao N, Di R, Xie AM, et al. Effect of vitrectomy timing on long-term efficacy in patients with vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Int Eye Sci, 2017, 17(9): 1738-1740. DOI: 10.3980/j.issn.1672-5123.2017.9.34.
6. Fassbender JM, Ozkok A, Canter H, et al. A comparison of immediate and delayed vitrectomy for the management of vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(1): 35-41. DOI: 10.3928/23258160-20151214-05.
7. Cheisson G, Jacqueminet S, Cosson E, et al. Perioperative management of adult diabetic patients. Preoperative period[J]. Anaesth Crit Care Pain Med, 2018, 37(Suppl 1): S9-19. DOI: 10.1016/j.accpm.2018.02.020.
8. Jinjing W, Kang C, Xufei L, et al. Chinese clinical practice guidelines for perioperative blood glucose management[J/OL]. Diabetes Metab Res Rev, 2021, 37(7): e3439[2021-02-19]. https://pubmed.ncbi.nlm.nih.gov/33605539/. DOI: 10.1002/dmrr.3439.
9. 中华医学会麻醉学分会. 围术期血糖管理专家共识(快捷版)[J]. 临床麻醉学杂志, 2016, 32(1): 93-95.Chinese Society of Anesthesiology. Expert consensus on perioperative blood glucose management (expression edition)[J]. J Clin Anesthesiol, 2016, 32(1): 93-95.
10. Qu J, Chen X, Liu Q, et al. Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: a randomized controlled trial[J/OL]. Front Public Health, 2022, 10: 1067670[2023-01-11]. https://pubmed.ncbi.nlm.nih.gov/36711366/. DOI: 10.3389/fpubh.2022.1067670.
11. Li S, Yang Y, Zou J, et al. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage[J]. BMC Ophthalmol, 2022, 22(1): 63. DOI: 10.1111/epi.17350.
12. Li B, Li MD, Ye JJ, et al. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy[J]. Chin Med J (Engl), 2020, 133(6): 664-669. DOI: 10.1177/0956462420932688.
13. Arevalo JF, Lasave AF, Kozak I, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial[J]. Am J Ophthalmol, 2019, 207: 279-287. DOI: 10.1016/j.ajo.2019.05.007.
14. Faisal SM, Tahir MA, Cheema AM, et al. Pars plana vitrectomy in vitreous hemorrhage with or without intravitreal bevacizumab a comparative overview[J]. Pak J Med Sci, 2018, 34(1): 221-225. DOI: 10.12669/pjms.341.12683.
15. Comyn O, Wickham L, Charteris DG, et al. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)[J]. Eye (Lond), 2017, 31(9): 1253-1258. DOI: 10.1038/eye.2017.75.
16. Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy[J/OL]. J Ophthalmol, 2016, 2016: 2473234[2016-03-13]. https://pubmed.ncbi.nlm.nih.gov/27034822/. DOI: 10.1155/2016/2473234.
17. Su L, Ren X, Wei H, et al. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy[J]. Retina, 2016, 36(5): 938-943. DOI: 10.1097/iae.0000000000000900.
18. Manabe A, Shimada H, Hattori T, et al. Randomized controlled study of intravitreal bevacizumab 0.16 mg injected one day before surgery for proliferative diabetic retinopathy[J]. Retina, 2015, 35(9): 1800-1807. DOI: 10.1097/IAE.0000000000000577.
19. Zaman Y, Rehman AU, Memon AF. Intravitreal avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy[J]. Pak J Med Sci, 2013, 29(2): 590-592. DOI: 10.12669/pjms.292.3044.
20. Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1[J]. Arch Ophthalmol, 2012, 130(9): 1127-1134. DOI: 10.1001/archophthalmol.2012.1611.
21. Farahvash MS, Majidi AR, Roohipoor R, et al. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage[J]. Retina, 2011, 31(7): 1254-1260. DOI: 10.1097/IAE.0b013e31820a68e5.
22. di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2010, 248(6): 785-791. DOI: 10.1007/s00417-010-1303-3.
23. Hernández-Da Mota SE, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2010, 20(6): 1047-1052. DOI: 10.1177/11206721 1002000604.
24. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
25. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(6): 837-842. DOI: 10.1007/s00417-008-0774-y.
26. Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial[J]. Ophthalmology, 2009, 116(10): 1943-1948. DOI: 10.1016/j.ophtha.2009.07.001.
27. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy[J]. Clin Ophthalmol, 2008, 2(4): 709-716.
28. Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy[J]. Ophthalmology, 2011, 118(11): 2218-2226. DOI: 10.1016/j.ophtha.2011.03.036.
29. Yang Z, Di Y, Ye J, et al. Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1171628[2023-05-26]. https://pubmed.ncbi.nlm.nih.gov/37305048/. DOI: 10.3389/fendo.2023.1171628.
30. Ding Y, Su N, Luan J, et al. Effect of intravitreal conbercept injection on complications of pars plana vitrectomy in patients with proliferative diabetic retinopathy[J]. J Pers Med, 2023, 13(4): 572. DOI: 10.3390/jpm13040572.
31. Wang DY, Zhao XY, Zhang WF, et al. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis[J/OL]. Sci Rep, 2020, 10(1): 18880[2020-11-03]. https://pubmed.ncbi.nlm.nih.gov/33144606/. DOI: 10.1038/s41598-020-75896-8.
32. Li H, Niu Y, Rong A, et al. Effect of adjunctive intravitreal conbercept injection at the end of 25G vitrectomy on severe proliferative diabetic retinopathy: 6-month outcomes of a randomised controlled trial[J]. Ophthalmol Ther, 2023, 12(2): 1173-1180. DOI: 10.1007/s40123-023-00664-6.
33. Jiang T, Gu J, Zhang P, et al. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study[J]. BMC Ophthalmol, 2020, 20(1): 43. DOI: 10.1186/s12886-020-1321-9.
34. Ren X, Bu S, Zhang X, et al. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy[J]. Eye (Lond), 2019, 33(7): 1177-1183. DOI: 10.1038/s41433-019-0396-0.
35. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA, 2015, 314(20): 2137-2146. DOI: 10.1001/jama.2015.15217.
36. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
37. Suzuki Y, Adachi K, Maeda N, et al. Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation[J]. Int J Retina Vitreous, 2020, 6: 24. DOI: 10.1186/s40942-020-00222-3.
38. Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy - the PRIDE study[J/OL]. Acta Ophthalmol, 2020, 98(5): e530-e539[2019-12-06]. https://pubmed.ncbi.nlm.nih.gov/31808278/. DOI: 10.1111/aos.14312.
39. Williams DF, Williams GA, Hartz A, et al. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique[J]. Ophthalmology, 1989, 96(6): 752-758. DOI: 10.1016/s0161-6420(89)32813-2.
40. Han DP, Murphy ML, Mieler WF. A modified en bloc excision technique during vitrectomy for diabetic traction retinal detachment. Results and complications[J]. Ophthalmology, 1994, 101(5): 803-808. DOI: 10.1016/s0161-6420(94)31255-3.
41. 黎晓新, 姜燕荣, 尹红, 等. 膜分割和膜清除方法对增生性糖尿病视网膜病变患者玻璃体手术效果的影响[J]. 中华眼科杂志, 2004, 40(7): 439-442. DOI: 10.3760/j:issn:0412-4081.2004.07.003.Li XX, Jiang YR, Yin H, et al. Influence of membrane dissection and en bloc excision on the outcome of vitreous surgery in proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2004, 40(7): 439-442. DOI: 10.3760/j:issn:0412-4081.2004.07.003.
42. 姚昱欧, 梁建宏, 黎晓新. 微切口玻璃体视网膜手术治疗增生型糖尿病视网膜病变合并牵拉性视网膜脱离的疗效观察[J]. 中华眼底病杂志, 2016, 32(5): 495-499. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.009.Yao YO, Liang JH, Li XX. Clinical effect of small-gauge vitrectomy for proliferative diabetic retinopathy with tractional retinal detachment[J]. Chin J Ocul Fundus Dis, 2016, 32(5): 495-499. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.009.
43. 梁建宏, 黎晓新. 增生型糖尿病视网膜病变玻璃体切割手术中眼内填充物和抗血管内皮生长因子药物应用利弊[J]. 中华眼底病杂志, 2016, 32(5): 527-528. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.016.Liang JH, Li XX. Advantages and disadvantages of intraocular fillers and anti-vascular endothelial growth factor drugs used in vitrectomy for proliferative diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2016, 32(5): 527-528. DOI: 10.3760/cma.j.issn.1005-1015.2016.05.016.
44. Meier P, Wiedemann P. Vitrectomy for traction macular detachment in diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 1997, 235(9): 569-574. DOI: 10.1007/BF00947086.
45. Kakehashi A. Total en bloc excision: a modified vitrectomy technique for proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2002, 134(5): 763-765. DOI: 10.1016/s0002-9394(02)01680-x.
46. 郑传珍, 任新军, 柯屹峰, 等. 最小量化玻璃体切除术治疗严重增生性糖尿病视网膜病变的初步观察[J]. 中华眼科杂志, 2021, 57(6): 440-446. DOI: 10.3760/cma.j.cn112142-20200812-00538.Zheng CZ, Ren XJ, Ke YF, et al. Minimally invasive vitrectomy for the treatment of severe proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2021, 57(6): 440-446. DOI: 10.3760/cma.j.cn112142-20200812-00538.
47. Vaziri K, Schwartz SG, Kishor KS, et al. Tamponade in the surgical management of retinal detachment[J]. Clin Ophthalmol, 2016, 10: 471-476. DOI: 10.2147/OPTH.S98529.
48. Kreissig I. The perfluorocarbon gases[M]//Kreissig I. Practical guide to minimal surgery for retinal detachment. 1st ed. Stuttgart: Thieme, 2000: 129-132.Kreissig I. The perfluorocarbon gases[M]//Kreissig I. Practical guide to minimal surgery for retinal detachment. 1st ed. Stuttgart: Thieme, 2000: 129-132.
49. Williamson TH. Principles of internal tamponade[M]//Williamson TH. Vitreoretinal surgery. 3rd ed. Berlin: Springer, 2021: 93-133.Williamson TH. Principles of internal tamponade[M]//Williamson TH. Vitreoretinal surgery. 3rd ed. Berlin: Springer, 2021: 93-133.
50. Balakrishnan D, Jain B, Nayaka A, et al. Role of tamponade in vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage[J]. Semin Ophthalmol, 2017, 32(4): 488-491. DOI: 10.3109/08820538.2015.1120757.
51. 陶勇, 姜燕荣, 黎晓新. 增生性糖尿病视网膜病变患者玻璃体手术不同眼内填充物的效果分析[J]. 眼科新进展, 2008, 28(2): 119-121. DOI: 10.3969/j.issn.1003-5141.2008.02.012.Tao Y, Jiang YR, Li XX. Different intraocular tamponade during vitrectomy on proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2008, 28(2): 119-121. DOI: 10.3969/j.issn.1003-5141.2008.02.012.
52. Rush RB, Velazquez JC, Rosales CR, et al. Gas tamponade for the prevention of postoperative vitreous hemorrhaging after diabetic vitrectomy: a randomized clinical trial[J]. Am J Ophthalmol, 2022, 242: 173-180. DOI: 10.1016/j.ajo.2022.06.015.
53. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2017, 237(4): 185-222. DOI: 10.1159/000458539.
54. Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group[J]. Eye (Lond), 2020, 34(Suppl 1): S1-51. DOI: 10.1038/s41433-020-0961-6.
55. Raizada S, Al Kandari J, Al Diab F, et al. Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional diabetic macular edema. A prospective, randomized comparative study[J]. Indian J Ophthalmol, 2015, 63(6): 504-510. DOI: 10.4103/0301-4738.162602.
56. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema[J]. Retina, 2008, 28(3): 420-426. DOI: 10.1097/IAE.0b013e318159e7d2.
57. Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial[J]. Graefe's Arch Clin Exp Ophthalmol, 2011, 249(7): 997-1008. DOI: 10.1007/s00417-010-1610-8.
58. Kumagai K, Furukawa M, Ogino N, et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema[J]. Retina, 2009, 29(4): 464-472. DOI: 10.1097/IAE.0b013e31819c632f.
59. Kumagai K, Hangai M, Ogino N, et al. Effect of interal limiting membrane peeling on long-term visual outcomes for diabetic macular edema[J]. Retina, 2015, 35(7): 1422-1428. DOI: 10.1097/IAE.0000000000000497.
60. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema[J]. Retina, 2006, 26(1): 5-13. DOI: 10.1097/00006982-200601000-00002.
61. Yamakoshi T, Kachi S, Sugita J, et al. Triamcinolone-assisted removal of internal limiting membrane enhances the effect of vitrectomy for diabetic macular edema[J]. Ophthalmic Res, 2009, 41(4): 203-209. DOI: 10.1159/000217724.
62. Yamamoto T, Hitani K, Sato Y, et al. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal[J]. Ophthalmologica, 2005, 219(4): 206-213. DOI: 10.1159/000085729.
63. Browning DJ, Lee C, Stewart MW, et al. Vitrectomy for center-involved diabetic macular edema[J]. Clin Ophthalmol, 2016, 10: 735-742. DOI: 10.2147/OPTH.S104906.
64. Lee JY, Jeong HS, Lee DY, et al. Early postoperative intraocular pressure stability after combined 23-gauge sutureless vitrectomy and cataract surgery in patients with proliferative diabetic retinopathy[J]. Retina, 2012, 32(9): 1767-1774. DOI: 10.1097/IAE.0b013e3182475ad6.
65. Park SP, Ahn JK, Lee GH. Morphologic changes in the anterior segment after phacovitrectomy for proliferative diabetic retinopathy[J]. J Cataract Refract Surg, 2009, 35(5): 868-873. DOI: 10.1016/j.jcrs.2008.12.032.
66. Kadonosono K, Matsumoto S, Uchio E, et al. Iris neovascularization after vitrectomy combined with phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy[J]. Ophthalmic Surg Lasers, 2001, 32(1): 19-24. DOI: 10.3928/1542-8877-20010101-05.
67. Tseng HY, Wu WC, Hsu SY. Comparison of vitrectomy alone and combined vitrectomy, phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy[J]. Kaohsiung J Med Sci, 2007, 23(7): 339-343. DOI: 10.1016/S1607-551X(09)70419-X.
68. 刘大川, 吴航, 郭丽. 玻璃体切除联合白内障手术治疗增生性糖尿病视网膜病变的临床效果[J]. 中华眼科杂志, 2007, 43(4): 346-349. DOI: 10.3760/j.issn:0412-4081.2007.04.012.Liu DC, Wu H, Guo L. Vitrectomy combined with phacoemulsification and intraocular lens implantation for treatment of proliferative diabetic retinopathy[J]. Chin J Ophthalmol, 2007, 43(4): 346-349. DOI: 10.3760/j.issn:0412-4081.2007.04.012.
69. 王萍, 陈松, 何广辉, 等. 不同联合手术方式治疗增生性糖尿病视网膜病变的有效性及并发症[J]. 国际眼科杂志, 2017, 17(5): 970-973. DOI: 10.3980/j.issn.1672-5123.2017.5.44.Wang P, Chen S, He GH, et al. Effect and complications of different combined surgeries for proliferative diabetic retinopathy[J]. Int Eye Sci, 2017, 17(5): 970-973. DOI: 10.3980/j.issn.1672-5123.2017.5.44.

Next Article
Evaluation of conjunctival sac culture findings prior to intravitreal injection

Chinese Journal of Ocular Fundus Diseases

Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content